Official PayPal Seal

AbbVie’s Product Concentration Risk Intensifies; Shares Yield ~3.9%

publication date: Mar 22, 2018
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

AbbVie will not seek accelerated approval for what had been expected to be its next blockbuster drug, Rova-T, which had been investigated for third-line relapsed/refractory small cell lung cancer. The market is reacting negatively to the disappointment.

Subscribe Now to Gain Access!

This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!

Click to Learn More about Valuentum

If you are already a subscriber, please

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.

To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.